| Date | Time | Source | | | 04/24/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community PR Newswire SAN DIEGO, April 24, 2024 WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share experiences and learn about current... More...>> |
| 04/23/2024 | 7:00AM | PRNUS | Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder PR Newswire SAN DIEGO, April 23, 2024 SAVITRI™ Study Met Primary Endpoint with Statistically Significant Reduction in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score at Day 28Met Key Secondary... More...>> |
| 04/16/2024 | 4:01PM | GLOBE | Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration... More...>> |
| 04/10/2024 | 4:01PM | PRNUS | Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results PR Newswire SAN DIEGO, April 10, 2024 Conference Call and Webcast Scheduled for Wednesday, May 1 SAN DIEGO, April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled... More...>> |
| 04/03/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder PR Newswire SAN DIEGO, April 3, 2024 SAN DIEGO, April 3, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized... More...>> |
| 03/28/2024 | 8:30AM | PRNUS | Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire SAN DIEGO, March 28, 2024 SAN DIEGO, March 28, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its... More...>> |
| 03/11/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March PR Newswire SAN DIEGO, March 11, 2024 UBS Virtual CNS Day 2024 Conference on March 18 Stifel 2024 Virtual CNS Days Conference on March 19 SAN DIEGO, March 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate... More...>> |
| 02/27/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Participate at Investor Conferences in March
Neurocrine Biosciences to Participate at Investor Conferences in March PR Newswire SAN DIEGO, Feb. 27, 2024 TD Cowen 44th Annual Healthcare Conference on March 5 in Boston Leerink Partners Global Biopharma Conference on March 12 in Miami Barclays 26th Annual Global Healthcare Conference on March 13 in Miami SAN DIEGO... More...>> |
| 02/07/2024 | 7:00AM | PRNUS | Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 PR Newswire SAN DIEGO, Feb. 7, 2024 INGREZZA® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion, Representing Year-over-Year Growth of 25% and 29... More...>> |
| 01/17/2024 | 4:16PM | PRNUS | Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results PR Newswire SAN DIEGO, Jan. 17, 2024 Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO, Jan. 17, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that... More...>> |
| 01/02/2024 | 4:01PM | PRNUS | Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 2, 2024 SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Tuesday January 9... More...>> |
| 12/06/2023 | 6:45AM | IHMARKETNEWS | Mastercard Boosts Buyback and Dividends, Bill Holdings Cuts Jobs, BOX, Asana, MongoDB Dip in Pre-Market, and Latest News
U.S. index futures are slightly up in Wednesday’s pre-market, with investors awaiting new employment data, and the Dow and S&P 500 recovering part of the drop from the last two days. At 5:53 AM, Dow Jones futures (DOWI:DJI) rose 47 points, or 0.13%. S&P 500 futures rose 0.26% and Nasdaq-100 futures increased... More...>> |
| 12/05/2023 | 4:53PM | DJN | Neurocrine Biosciences Gets FDA Breakthrough Therapy Status for Genetic Disorder Treatment
By Ben Glickman Neurocrine Biosciences has received breakthrough therapy designation for its treatment for congenital adrenal hyperplasia from the U.S. Food and Drug Administration. The San Diego-based biotechnology company said Tuesday it was on track to submit a new drug application for crinecerfont in the treatment... More...>> |
| 12/05/2023 | 4:01PM | PRNUS | Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia
Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, Dec. 5, 2023 Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinecerfont New Drug Application Submission... More...>> |
| 12/01/2023 | 7:00AM | PRNUS | Neurocrine Biosciences to Host Analyst Day on December 5, 2023
Neurocrine Biosciences to Host Analyst Day on December 5, 2023 PR Newswire SAN DIEGO, Dec. 1, 2023 SAN DIEGO, Dec. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&D portfolio and strategy on Tuesday... More...>> |
| 11/13/2023 | 7:00AM | PRNUS | Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation
Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire SAN DIEGO, Nov. 13, 2023 SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that is has resolved... More...>> |
| 11/09/2023 | 4:01PM | PRNUS | Neurocrine Biosciences Provides Development Pipeline Update
Neurocrine Biosciences Provides Development Pipeline Update PR Newswire SAN DIEGO, Nov. 9, 2023 Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-1065846 in Patients with Anhedonia in Major... More...>> |
| 11/08/2023 | 4:05PM | PRNUS | Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia
Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia PR Newswire SAN DIEGO, Nov. 8, 2023 SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the availability of... More...>> |
| 11/08/2023 | 4:01PM | PRNUS | Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference PR Newswire SAN DIEGO, Nov. 8, 2023 SAN DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2023 at 3:00 p.m. Greenwich Mean Time... More...>> |
| 11/02/2023 | 8:30AM | PRNUS | Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023
Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 PR Newswire SAN DIEGO, Nov. 2, 2023 SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:... More...>> |
|